Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引:33
作者
Kita, Mariko [1 ]
Fox, Robert J. [2 ]
Phillips, J. Theodore [3 ]
Hutchinson, Michael [4 ]
Havrdova, Eva [5 ]
Sarda, Sujata P. [6 ]
Agarwal, Sonalee [6 ]
Kong, Jessica [6 ]
Zhang, Annie [6 ]
Viglietta, Vissia [6 ]
Sheikh, Sarah I. [6 ]
Seidman, Emily [7 ]
Dawson, Katherine T. [6 ]
机构
[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA
[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland
[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[6] Biogen Idec Inc, Cambridge, MA USA
[7] CircleSci, Tytherington, England
关键词
Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;
D O I
10.1177/1352458513507818
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.
引用
收藏
页码:253 / 257
页数:5
相关论文
共 50 条
[41]   The influence of personality traits and coping strategies on the quality of life of patients with relapsing-remitting type of multiple sclerosis [J].
Krstic, Dragan ;
Krstic, Zvezdana D. ;
Stojanovic, Zvezdana ;
Kolundzija, Ksenija ;
Stojkovic, Mirjana ;
Dincic, Evica .
VOJNOSANITETSKI PREGLED, 2021, 78 (08) :805-810
[42]   Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) [J].
Gold, Ralf ;
Giovannoni, Gavin ;
Phillips, J. Theodore ;
Fox, Robert J. ;
Zhang, Annie ;
Meltzer, Leslie ;
Kurukulasuriya, Nuwan C. .
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) :57-66
[43]   Health-related quality of life in Japanese patients with multiple sclerosis [J].
Niino, Masaaki ;
Fukumoto, Shoko ;
Okuno, Tatsusada ;
Sanjo, Nobuo ;
Fukaura, Hikoaki ;
Mori, Masahiro ;
Ohashi, Takashi ;
Takeuchi, Hideyuki ;
Shimizu, Yuko ;
Fujimori, Juichi ;
Kawachi, Izumi ;
Kira, Jun-Ichi ;
Takahashi, Eri ;
Miyazaki, Yusei ;
Mifune, Nobuhiro .
JOURNAL OF NEUROLOGY, 2023, 270 (02) :1011-1018
[44]   Health-related quality of life in Japanese patients with multiple sclerosis [J].
Masaaki Niino ;
Shoko Fukumoto ;
Tatsusada Okuno ;
Nobuo Sanjo ;
Hikoaki Fukaura ;
Masahiro Mori ;
Takashi Ohashi ;
Hideyuki Takeuchi ;
Yuko Shimizu ;
Juichi Fujimori ;
Izumi Kawachi ;
Jun-ichi Kira ;
Eri Takahashi ;
Yusei Miyazaki ;
Nobuhiro Mifune .
Journal of Neurology, 2023, 270 :1011-1018
[45]   Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study [J].
Ernst, Frank R. ;
Barr, Peri ;
Elmor, Riad ;
Wong, Schiffon L. .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) :2099-2106
[46]   Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE) [J].
Gold, Ralf ;
Schlegel, Eugen ;
Elias-Hamp, Birte ;
Albert, Christian ;
Schmidt, Stephan ;
Tackenberg, Bjoern ;
Xiao, James ;
Schaak, Tom ;
Salmen, Hans Christian .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[47]   Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC [J].
Berger, T. ;
Brochet, B. ;
Brambilla, L. ;
Giacomini, P. S. ;
Montalban, X. ;
Salgado, A. Vasco ;
Su, R. ;
Bretagne, A. .
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (04)
[48]   Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial [J].
Robinson, D., Jr. ;
Zhao, N. ;
Gathany, T. ;
Kim, L. -L. ;
Cella, D. ;
Revicki, D. .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) :1121-1130
[49]   Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies [J].
Havrdova, E. ;
Giovannoni, G. ;
Gold, R. ;
Fox, R. J. ;
Kappos, L. ;
Phillips, J. Theodore ;
Okwuokenye, M. ;
Marantz, J. L. .
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (05) :726-733
[50]   Research Paper: The Relationship Between Balance and Activities of Daily Living With the Quality of Life of Patients With Relapsing-Remitting Multiple Sclerosis [J].
Noon, Mansour ;
Hosseini, Seyed Ali ;
Shiri, Vali ;
Akbarfahimi, Nazila .
ARCHIVES OF REHABILITATION, 2019, 19 (04) :292-301